Lupin Ltd. 在全球制药公司中名列前茅,印度在2025年S&P可持续性评估中名列第一,ESG业绩评分为91/100。 Lupin Ltd. ranked top globally in pharmaceuticals and India in S&P’s 2025 sustainability assessment, scoring 91/100 for ESG performance.

Lupin有限公司在2025年S & P全球公司可持续性评估中被命名为世界顶尖制药公司和印度所有部门的领先者,在100项中得分91分。 Lupin Limited has been named the world’s top pharmaceutical company and leader across all sectors in India in the S&P Global Corporate Sustainability Assessment 2025, scoring 91 out of 100. 这一成就使鲁邦在全球公司中名列前茅的1%,并在《2026年科技可持续发展年鉴》中连续第三年取得这一成绩。 The achievement places Lupin in the top 1% of global companies and marks its third consecutive year in the S&P Sustainability Yearbook 2026. 评估评估了各公司对其工业所特有的经济、环境和社会因素的评价。 The assessment evaluates firms on economic, environmental, and social factors specific to their industries. Lupin的承认反映了其对环境管理、强有力的治理和社会影响的持续承诺,强调其将环境、社会和治理原则纳入其全球业务的长期战略。 Lupin’s recognition reflects its sustained commitment to environmental stewardship, strong governance, and social impact, underscoring its long-term strategy to integrate ESG principles across its global operations.